// App-Quantinova.ai

551 : Optimal endocrine therapy for breast cancer patients 45-50 years of age at diagnosis.

Researchers

Presenter

  • Gwen Dackus

Principal Investigators

  • Katarzyna Jozwiak

  • Gabe S. Sonke

  • Elsken Van Der Wall

  • Paul J. van Diest

  • Sabine Siesling

  • Michael Hauptmann

  • Sabine C. Linn

Medical Centers

  • Division of Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital, Amsterdam, Netherlands

  • Department of Epidemiology and Biostatistics, Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital, Amsterdam, Netherlands

  • Department of Radiation Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands

  • Division of Internal Medicine and Dermatology, University Medical Center Utrecht, Utrecht, Netherlands

  • Department of Pathology, University Medical Center Utrecht, Utrecht, Netherlands

  • Department of Research, Comprehensive Cancer Center the Netherlands, Utrecht, Netherlands

  • Department of Epidemiology and Biostatistics, Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital, Amsterdam, Netherlands

Locations

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Progesterone receptor

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Trastuzumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved